KDM5-C70

Name: KDM5-C70
Brand: MedChemExpress
SKU: HY-120400
Rating: 5.0 (8 reviews)

Cat. No.: HY-120400 Purity: 98.82%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels.

For research use only. We do not sell to patients.

CAS No. : 1596348-32-1

Size	Stock	Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Liquid
25 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

8 Publications Citing Use of MCE KDM5-C70

Cell Imaging/Staining

RT-PCR

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Feb 13;15(1):5409. [Abstract]; NSCs treated with 0.1% DMSO (Upper row) or 25 µM KDM5-C70 (Lower row) in the absence of EGF and FGF2 for 4 days. (a) nuclei stained with DAPI (blue), (b) astrocytes immuno-stained with GFAP (red), (c) neurons immuno-stained with TuJ1 (green), and (d) merged images.

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Feb 13;15(1):5409. [Abstract]; Real-time RT-PCR was performed to quantify the mRNA levels of Gfap. Total RNA was extracted from NSCs treated with 0.1% DMSO or 25 µM KDM5-C70 in the absence of EGF and FGF2 for 3 days. Gapdh was used as an internal control.

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 May;33(5):403-406. [Abstract]; Western blotting was performed in mRBBP5-dTAG mESCs treated with dTAG and/or pan-KDM5 inhibitor KDM5-C70 for 12 h. The results showed that supplementation with KDM5-C70 reversed the reduction of global H3K4me2/3 induced by 12 h dTAG treatment.

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 May;33(5):403-406. [Abstract]; Western blotting of dTAG treatment with or without pan-KDM5 inhibition by KDM5-C70 (12 h) in mRBBP5-dTAG mESCs. The results showed that treatment with the pan-KDM5 inhibitor KDM5-C70 restored H3K4me3 levels, indicating that KDM5 demethylases are mainly responsible for RBBP5 degradation-induced rapid H3K4me3 depletion.

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Apr 7;9(14):eadd8343. [Abstract]; The treatment of pan-Kdm5 histone demethylase inhibitor KDM5-C70 partially rescued the mushroom morphology of te×ls embryos. The te×ls embryos were treated with KDM5-C70 (20 μM) from stage 3, and images were captured at stage 11.

: KDM5-C70 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2023 Apr 7;9(14):eadd8343. [Abstract]; The H3K4me3 and Mdm2 protein levels in te×ls embryos upon KDM5-C70 (10-20 μM) treatment were detected by western blot around stage 11. The results showed that elevations of H3K4me3 and Mdm2 were observed in KDM5-C70–treated te×ls embryos.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Demethylase Isoform Specific Products:

View All Isoforms

KDM1/LSD1 KDM2 KDM3 KDM4 KDM5 KDM6 KDM7

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

KDM5

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	<1 μM Compound: 130	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 120 hrs by ATPlite assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 120 hrs by ATPlite assay	[PMID: 26710088]
MM1.S	EC₅₀	3.1 μM Compound: 14	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability	[PMID: 34555614]
U2OS	IC₅₀	<1 μM Compound: 130	Inhibition of KDM5B in human U2OS cells assessed as reduction in demethylation of H3K4me3 after 20 hrs by Hoechst 33342 staining based immunofluorescence assay Inhibition of KDM5B in human U2OS cells assessed as reduction in demethylation of H3K4me3 after 20 hrs by Hoechst 33342 staining based immunofluorescence assay	[PMID: 26710088]
U2OS	IC₅₀	<1 μM Compound: 130	Inhibition of KDM5C in human U2OS cells assessed as reduction in demethylation of H3K4me3 after 20 hrs by Hoechst 33342 staining based immunofluorescence assay Inhibition of KDM5C in human U2OS cells assessed as reduction in demethylation of H3K4me3 after 20 hrs by Hoechst 33342 staining based immunofluorescence assay	[PMID: 26710088]

In Vitro

KDM5-C70 (10^-9-10^-5 M; 7 days; MM.1S myeloma cells) treatment shows antiproliferative effects after 7 days of treatment at elevated concentrations (estimated 50% reduction of viability/proliferation for KDM5-C70 at ~20 μM)^[1].
KDM5-C70 (50 μM; 7 days; MM.1S myeloma cells) treatment decreases the level of phosphorylation of retinoblastoma protein (Rb), while leaving the total level of phosphorylated Rb (pRb) unchanged, indicating impairment of cell cycle progression^[1].
Chromatin immunoprecipitation followed by next-generation sequencing shows an increase in H3K4me3 levels around transcription start sites with KDM5-C70 but little change with GSK467A at 50 μM inhibitor concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MM.1S myeloma cells
Concentration:	10^-9-10^-5 M
Incubation Time:	7 days
Result:	Showed antiproliferative effects after 7 days of treatment at elevated concentrations.

Western Blot Analysis^[1]

Cell Line:	MM.1S myeloma cells
Concentration:	50 μM
Incubation Time:	7 days
Result:	Decreased the level of phosphorylation of retinoblastoma protein (Rb).

Molecular Weight

336.43

Formula

C₁₇H₂₈N₄O₃

CAS No.

1596348-32-1

Appearance

Liquid (Density: 1.099 g/cm³)

Color

Light yellow to yellow

SMILES

O=C(C1=CC(CNCC(N(CCN(C)C)CC)=O)=NC=C1)OCC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (297.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9724 mL	14.8619 mL	29.7239 mL
5 mM	0.5945 mL	2.9724 mL	5.9448 mL
10 mM	0.2972 mL	1.4862 mL	2.9724 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.82%

Select Batch:

Data Sheet (272 KB) SDS (393 KB)

COA (243 KB) HNMR (351 KB) RP-HPLC (269 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Johansson C, et al. Structural analysis of human KDM5B guides histone demethylase inhibitor development. Nat Chem Biol. 2016 Jul;12(7):539-45. [Content Brief]

[2]. Blair LP, et al. KDM5 lysine demethylases are involved in maintenance of 3'UTR length. Sci Adv. 2016 Nov 18;2(11):e1501662. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9724 mL	14.8619 mL	29.7239 mL	74.3097 mL
	5 mM	0.5945 mL	2.9724 mL	5.9448 mL	14.8619 mL
	10 mM	0.2972 mL	1.4862 mL	2.9724 mL	7.4310 mL
	15 mM	0.1982 mL	0.9908 mL	1.9816 mL	4.9540 mL
	20 mM	0.1486 mL	0.7431 mL	1.4862 mL	3.7155 mL
	25 mM	0.1189 mL	0.5945 mL	1.1890 mL	2.9724 mL
	30 mM	0.0991 mL	0.4954 mL	0.9908 mL	2.4770 mL
	40 mM	0.0743 mL	0.3715 mL	0.7431 mL	1.8577 mL
	50 mM	0.0594 mL	0.2972 mL	0.5945 mL	1.4862 mL
	60 mM	0.0495 mL	0.2477 mL	0.4954 mL	1.2385 mL
	80 mM	0.0372 mL	0.1858 mL	0.3715 mL	0.9289 mL
	100 mM	0.0297 mL	0.1486 mL	0.2972 mL	0.7431 mL

KDM5-C70 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KDM5-C701596348-32-1Histone DemethylaseKDM5JARID1antiproliferativephosphorylationretinoblastomaH3K4me3KDM5-C49Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

KDM5-C70

Customer Review

KDM5-C70 Related Antibodies

8 Publications Citing Use of MCE KDM5-C70

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Demethylase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

KDM5-C70 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

KDM5-C70 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report